Everolimus: preventing organ rejection in adult kidney transplant recipients

Bibliography

• Hariharan S, Johnson CP, Bresnahan B, Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche H, Schold J, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95
   PubMed Web of Science ®Google Scholar
• Gallagher M, Jardine M, Perkovic V, Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009;87:1877-83
   PubMedGoogle Scholar
• Chapman J, O'Connel P, Nankivell B. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16:3015-26
   PubMed Web of Science ®Google Scholar
• Pascual M, Theruvath T, Kawai T, Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002;436:580-90
   Google Scholar
• Nankivell B, Borrows R, Fung C, The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33
   PubMedGoogle Scholar
• Snanoudj R, Royal V, Elie C, Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011;11:2635-346
   PubMed Web of Science ®Google Scholar
• El-Zoghby Z, Stegall M, Lager D, Identifying specific causes of kidney allograft loss. Am J Transplant 2009;9:527-35
   PubMed Web of Science ®Google Scholar
• Nankivell B, Borrows R, Fung C, Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557-65
   PubMed Web of Science ®Google Scholar
• Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004;43:953-65
   PubMed Web of Science ®Google Scholar
• Mathis A, Dave N, Knipp G, Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004;61:565-85
   PubMed Web of Science ®Google Scholar
• Mangray M, Vella J. Hypertension after kidney transplant. Am J Kidney Dis 2011;57:331-41
   PubMed Web of Science ®Google Scholar
• Vajdic C, McDonald S, McCredie M, Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31
   PubMed Web of Science ®Google Scholar
• Collett D, Mumford L, Banner N, Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant 2010;10:1889-96
   PubMed Web of Science ®Google Scholar
• Pilmore H, Dent H, Chang S, Reduction of cardiovascular death after kidney transplantation. Transplantation 2009;89:851-7
   Google Scholar
• Hojo M, Morimoto T, Maluccio M, Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4
   PubMed Web of Science ®Google Scholar
• Guba M, von Breitenbuch P, Steinbauer M, Rapamycin inhibits primary and metastatic tumor growth by angiogenesis; involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35
   PubMed Web of Science ®Google Scholar
• Vitko S, Margreiter R, Weimar W, Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant recipients. Am J Transplant 2005;5:2521-30
   PubMed Web of Science ®Google Scholar
• Kovaric J, Kaplan B, Tedesco Silva H, Exposure-response relationships for everolimus in de novo kidney transplantation defining a therapeutic range. Transplantation 2002;27:920-5
   Google Scholar
• Lorber M, Mulgaonkar S, Butt K, Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-52
   PubMed Web of Science ®Google Scholar
• Taylor A, Watson C, Bradley J. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005;56:23-46
   PubMed Web of Science ®Google Scholar
• Thomson A, Turnquist H, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009;9:324-37
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, SDZ-RAD, a new rapamycin derivate: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42
   PubMed Web of Science ®Google Scholar
• Sanchez-Fructuoso A. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2008;4:807-19
   PubMed Web of Science ®Google Scholar
• Kirchner G, Meier-Wiedenbach I, Manns M, Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95
   PubMed Web of Science ®Google Scholar
• Kovarick J, Curtis J, Hricik D, Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006;38:3456-8
   PubMedGoogle Scholar
• Kovarik J, Sabia H, Figueiredo J, Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001;70:425-30
   PubMed Web of Science ®Google Scholar
• Kaplan B, Tedesco-Silva H, Mendez R, North/South American, double blind, parrallel group study of the safety and efficacy of Certican (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral and corticosteroids (abstract n°1339). Am J Transplant 2001;1(Suppl 1):475
   Google Scholar
• Vitko S, Margreiter R, Weimar W, Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004;78:1532-40
   PubMed Web of Science ®Google Scholar
• Lorber M, Ponticelli C, Whelchel J, Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy and safety data. Clin Transplant 2005;19:145-52
   PubMed Web of Science ®Google Scholar
• Kuypers D. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005;28:153-81
   PubMed Web of Science ®Google Scholar
• Nashan B, Curtis J, Ponticelli C, Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three year phase II, randomized, multicenter, open-label study. Transplantation 2004;78:1332-40
   PubMed Web of Science ®Google Scholar
• Hausen B, Gummert J, Berry G, Prevention of acute rejection in nonhuman primate lung transplant recipients; induction with chimeric anti-interleukine-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethl)-rapamycin. Transplantation 2000;27:488-96
   Google Scholar
• Vincenti F, Ramos E, Brattstrom C, Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-7
   PubMed Web of Science ®Google Scholar
• Vitko S, Tedesco H, Eris J, Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6 months safety and efficacy results of two randomized studies. Am J Transplant 2004;4:626-35
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Vitko S, Pascual J, 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007;20:27-36
   PubMed Web of Science ®Google Scholar
• Salvadori M, Scolari M, Bertoni E, Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter randomized, controlled trial. Transplantation 2010;88:1194-202
   Google Scholar
• Ponticelli C, Salvadori M, Scolari M, Everolimus and Minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study. Transplantation 2011;91:72-3
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Cibrik D, Johnston T, Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard exposure to CsA in renal-transplant recipients. Am J Transplant 2010;10:1401-14
   PubMedGoogle Scholar
• Dumont F, Melino M, Staruch M, FK506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990;144:1418-24
   PubMed Web of Science ®Google Scholar
• Vu M, Qi S, Xu D, Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997;64:1853-6
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche H, Schold J, Srinivas T, Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycofenolate mofetil combined with tacrolimus. Am J Transplant 2005;5:2273-80
   PubMed Web of Science ®Google Scholar
• Pascual J, del Castillo D, Cabello M, Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation 2010;89:994-1000
   PubMed Web of Science ®Google Scholar
• Kovaric J, Beyer D, Schmouder R. Everolimus drug interactions: application of a classification system for a clinical decision making. Biopharm Drug Dispo 2006;27:421-6
   PubMedGoogle Scholar
• Chan L, Greenstein S, Hardy M, Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrate its effectiveness. Transplantation 2008;85:821-6
   PubMed Web of Science ®Google Scholar
• Vitko S, Hene R, Langer R, Everolimus with low or very low exposure of tacrolimus in de novo renal transplant recipients: the ASSET study (abstract 201). Transpl Int 2009;22:53
   Google Scholar
• Russ G. Stratifying risk and targeting immunosuppressive strategies. Transplant Proc 2008;40:S60-2
   PubMedGoogle Scholar
• Schena F, Pascoe M, Alberu J, Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24 month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-42
   PubMed Web of Science ®Google Scholar
• Holdaas H, Rostaing L, Seron D, Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24 month study. Transplantation 2011;92:410-18
   PubMed Web of Science ®Google Scholar
• Budde K, Becker T, Arns W, Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011;377:837-47
   PubMed Web of Science ®Google Scholar
• Holdaas H, Bentdal O, Pfeffer P, Early abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008;22:366-71
   PubMed Web of Science ®Google Scholar
• Bemelman F, de Maar E, Press R, Minimization of maintenance immunossuppression early after renal transplantation: an interim analysis. Transplantation 2009;88:421-8
   PubMed Web of Science ®Google Scholar
• van der Heide H, de Fijter J, de Maar E, Low acute rejection rate and superior renal function 2 years after early CsA withdrawal and overnight switch to everolimus (abstract n° 1654). Am J Transplant 2010;10:508
   Google Scholar
• Kovarik J, Dantal J, Civati G, Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplanted patien ts. Am J Transplant 2003;3:1576-80
   PubMed Web of Science ®Google Scholar
• Legendre C, Nashan B, Holdaas H. Ongoing studies to explore the role of everolimus in renal transplantation. Transplantation 2011;92:S18-26
   PubMedGoogle Scholar
• Terasaki P, Cai J. Human leucocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008;86:377-83
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Hof A, Baumlin Y, Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice. Transplantation 2003;76:1166-70
   PubMed Web of Science ®Google Scholar
• Joannides R, Monteil C, H. de Ligny B, Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1 year non randomized controlled trial. Am J Kidney Dis 2008;52:324-30
   PubMedGoogle Scholar
• Joannides R, Monteil C, de Ligny, et al. Immunosuppressant regimen based on sirolimus decrease aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 2011;11:2414-22
   PubMed Web of Science ®Google Scholar
• Seckinger J, Sommerer C, Hinkel U, Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008;26:2213-19
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer H, Legendre C, Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-70
   PubMed Web of Science ®Google Scholar
• Brennan D, Legendre C, Patel D, Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplanted: pooled analysis of three clinical trials. Am J Transplant 2011;11:2453-62
   PubMedGoogle Scholar
• Vasudev B, Hariharan S, Hussain S, BK virus nephritis: risk factors, timing, and outcomes in renal transplant recipients. Kidney Int 2005;68:1834-9
   PubMed Web of Science ®Google Scholar
• Wali R, Drachenberg C, Hirsch H, BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004;78:1069-73
   PubMed Web of Science ®Google Scholar
• Dharnidharka B, Cherikh W, Abbott K. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009;87:1019-26
   PubMed Web of Science ®Google Scholar
• Schold J, Rehman S, Kayler L, Treatment for BK virus: incidence, risk factors, and outcomes for kidney transplant recipients in the United States. Transpl Int 2009;22:626-34
   PubMed Web of Science ®Google Scholar
• Geissler E, Schlitt H, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008;8:1-7
   Google Scholar
• Wong G, Chapman J. Cancer after renal transplantation. Transpl Rev 2008;22:141-9
   Google Scholar
• Kauffmann H, Cherikh W, Cheng Y, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9
   PubMedGoogle Scholar
• Alberu J, Pascoe M, Campistol J, Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24 month results from the CONVERT trial. Transplantation 2011;92:303-10
   PubMed Web of Science ®Google Scholar
• Sampaio M, Cho Y, Shah T, Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 2012;93:73-81
   PubMed Web of Science ®Google Scholar
• Motzer R, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Valente J, Hricik D, Weigel K, Comparison of sirolimus vs. Mycophenolte mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003;3:1128-34
   PubMed Web of Science ®Google Scholar
• Stallone G, Di Paolo S, Schena A, Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004;15:228-33
   PubMed Web of Science ®Google Scholar
• Margreiter R, Vitko S, Whelchel J, Post-operative tissue regeneration in renal transplantation: comparable outcome with everolimus or MMF. (abstract). Transplantation 2008;86:188
   Google Scholar
• Albano L, Berthoux F, Moal M-C, Incidence of delayed graft function and wound healing complications after decreased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009;88:69-76
   PubMed Web of Science ®Google Scholar
• Wilmer W, Rovin B, Hebert C, Management of glomerular proteinuria; a commentary. J Am Soc Nephrol 2003;14:3217-32
   PubMed Web of Science ®Google Scholar
• Schena F, Pascoe M, Alberu J, Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-months efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-42
   PubMed Web of Science ®Google Scholar
• Sartelet H, Toupance O, Lorenzato M, Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial factor in kidneys. Am J Transplant 2005;5:2441-7
   PubMed Web of Science ®Google Scholar
• Morrisett J, Abdel-Fattah G, Hoogeveen R, Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002;43:1170-80
   PubMed Web of Science ®Google Scholar
• Kovaric J, Hartmann S, Hubert M, Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministred with everolimus. J Clin Pharmacol 2002;42:222-8
   PubMedGoogle Scholar
• Teutonico A, Schena P, DiPaolo S. Glucose metabolism in renal transplant recipients; effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-35
   PubMed Web of Science ®Google Scholar
• Johnston O, Rose C, Webster A, Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-18
   PubMed Web of Science ®Google Scholar
• Cibrik D, Arcona S, Vasquez E, Long-term experience with everolimus in kidney transplantation in the United States. Transplant Proc 2011;43:2562-7
   PubMedGoogle Scholar
• Campistol J, de Fijter J, Flechner S, mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010;24:149-56
   PubMed Web of Science ®Google Scholar
• Pascual J, Marcen R, Ortuno J. Clinical experience with everolimus (certican): optimizing dose and tolerability. Transplantation 2005;79:S80-4
   PubMed Web of Science ®Google Scholar
• Morelon E, Stern M, Israel-Biet D, Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72:787-90
   PubMed Web of Science ®Google Scholar
• De Simone P, Petruccelli S, Precisi A, Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient – not all proliferation signal inhibitors are the same – case report. Transplant Proc 2007;39:3500-1
   PubMed Web of Science ®Google Scholar
• Errasti P, Izquierdo D, Martin P, Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc 2010;42:3053-4
   PubMed Web of Science ®Google Scholar
• Kaczmarek I, Groetzner J, Adamidis I, Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004;4:1084-8
   PubMed Web of Science ®Google Scholar
• Kramer B, Neumayer H, Stahl R, Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine and basiliximab. Transplant Proc 2005;37:1601-4
   PubMed Web of Science ®Google Scholar
• Skrzypek J, Krause W. Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment. Andrologia 2007;39:198-9
   PubMed Web of Science ®Google Scholar
• Zuber J, Anglicheau D, Elie C, Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008;8:1471-9
   PubMed Web of Science ®Google Scholar
• Veroux M, Corona D, Veroux P. Pregnancy under everolimus-based immunosuppression. Transpl Int 2001;24:115-17
   Google Scholar
• Framarino dei Malatesta M, Corona L, De Luca L, Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. Transplantation 2011;91:69-71
   PubMed Web of Science ®Google Scholar
• Coscia L, Constantinescu S, Moritz M, Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: Ceska J, Terasaki P, editors. Clinical Transplants. UCLA Terasaki Foundation Laboratory; Los Angeles, CA: 2010. p. 113-22
   Google Scholar